-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guide: ZD03 is primarily used in the treatment of multiple sclerosis (Multiple Sclerosis, MS).
Shanxi Zhendong Pharmaceutical Co., Ltd. announced on August 3 that the company's new drug ZD03 for the treatment of multiple sclerosis has been approved for clinical trials.
Shanxi Zhendong Pharmaceutical Co., Ltd., a subsidiary of Shanxi Zhendong Pharmaceutical Co., Ltd., submitted to the State Drug Administration on May 8, 2020 the application for zD03 new drug IND (Investigational New Drug) application and acceptance;
small molecule drugs developed by zhendong Pilot, a new type of chemical structure derived from natural products, mainly for the treatment of multiple sclerosis (MULTIPLE Sclerosis, MS).
multiple sclerosis is an immune-mediated chronic inflammatory demyelinopathy disease of the central nervous system, which has high characteristics in Caucasian strains in Europe and america.
ZD03 has the same action target as MS's first-line drug fumariat, but ZD03 has higher selectivity and lower effective dose, thus providing more effective means for the clinical treatment of MS.
queryglobaldata database, global sales of fumarite in 2019 were $4.487 billion, up 3.8% year-on-year.
.